RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that ... · ACCESS Newswire · Amphastar Pharmaceuticals, Inc. Amphastar ...
Inhalation: The recommended dose (ipratropium bromide nasal spray 0.03%) is two sprays (42 mcg) per nostril two or three times daily (total dose 168 to 252 mcg/day).
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Atrovent Inhalation Solution? Atrovent Inhalation ...
Learn everything you need to know about Ipratropium Bromide-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...
RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...
The FDA has advised consumers not to use albuterol sulfate inhalation solution, 0.083%, and ipratropium bromide inhalation solutions, 0.02%, unit-dose vials, purchased after September 8, 2009 and ...
Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...
Pharma major Lupin Ltd on Friday said it has launched Ipratropium Bromide nasal spray, used in treatment of runny nose, in the US market. The Ipratropium Bromide nasal solution (nasal spray) launched ...
October 7, 2011 — The US Food and Drug Administration (FDA) has granted approval for an ipratropium bromide and albuterol sulfate inhalation spray (Combivent Respimat Inhalation Spray, Boehringer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results